On 7/11/24, VistaGen Therapeutics Inc (NASDAQ: VTGN) stock enjoyed a major increase of 12.4%, closing at $3.91. Moreover, this advance was accompanied by exceptionally high trading volume at 221% of normal. The stock has performed in line with the market over the last nine months and has risen 17.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, VTGN is expected to be a modest Value Eraser.
VistaGen Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. VistaGen Therapeutics has a neutral Power Rating of 50 but a very low Appreciation Score of 5, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment